{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:13:49Z","timestamp":1791054829755,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Immunex (a subsidiary of Amgen Inc.)"},{"name":"Pfizer (previously Wyeth)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate adherence and persistence with etanercept plus methotrexate (ETN\u2010MTX) combination therapy and MTX, hydroxychloroquine, and sulfasalazine triple therapy at 1 year following treatment initiation in adults with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis used data from the Truven Health MarketScan Commercial and Medicare Supplemental databases from January 2009 to July 2013. Adherence was defined as having percentage of days covered &gt;80% for all drugs within each regimen. Persistence was defined as no treatment gap &gt;45 days for any drug and no addition or switching to other disease\u2010modifying antirheumatic drugs. Multiple logistic regression models were employed in the analyses to control for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3,724 ETN\u2010MTX patients and 818 triple therapy patients were eligible. At 1 year, 27.9% who were taking ETN\u2010MTX and 18.2% using triple therapy were adherent to all agents in their regimen (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001), and 29.4% who were taking ETN\u2010MTX and 23.2% using triple therapy were persistent (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). After adjusting for confounders, ETN\u2010MTX patients had significantly greater odds of being adherent (odds ratio [OR] 1.79, 95% confidence interval [95% CI] 1.47\u20132.17) and persistent (OR 1.45, 95% CI 1.20\u20131.72) compared with patients using triple therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with RA initiating treatment with ETN\u2010MTX combination therapy demonstrated greater adherence and persistence at 1 year than patients initiating triple therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.22638","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T04:13:18Z","timestamp":1434773598000},"page":"1656-1663","source":"Crossref","is-referenced-by-count":33,"title":["Etanercept\u2010Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis"],"prefix":"10.1002","volume":"67","author":[{"given":"Machaon","family":"Bonafede","sequence":"first","affiliation":[{"name":"Truven Health Analytics Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Truven Health Analytics Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek H.","family":"Tang","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Shah","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Collier","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"e_1_2_8_4_1","volume-title":"Enbrel (etanercept) prescribing information","year":"2013"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11142"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303006"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34498"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081204"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.10.15"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i27.4344"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.01.011"},{"key":"e_1_2_8_15_1","first-page":"686","article-title":"Retention rates of disease\u2010modifying anti\u2010rheumatic drugs in patients with rheumatoid arthritis","volume":"50","author":"Agarwal S","year":"2009","journal-title":"Singapore Med J"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20484"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2013.793"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37917"},{"key":"e_1_2_8_19_1","first-page":"748","article-title":"Persistence on therapy is a major determinant of patient\u2010, physician\u2010 and laboratory\u2010reported outcomes in recent\u2010onset rheumatoid arthritis patients","volume":"28","author":"Contreras\u2010Yanez I","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181e8bcb0"},{"key":"e_1_2_8_21_1","first-page":"457","article-title":"Measuring concurrent adherence to multiple related medications","volume":"15","author":"Choudhry NK","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00056-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.18.1458"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199803000-00012"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.3.332"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3471"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/NOR.0b013e3181e5c2c9"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.23"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2162-x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0003-4967(24)43387-6","article-title":"Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial","volume":"60","author":"Hill J","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.3.146"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2013.12.002"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/msc.141"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00601.x"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22638","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.22638","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:07:18Z","timestamp":1759417638000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/acr.22638"],"URL":"https:\/\/doi.org\/10.1002\/acr.22638","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}